Estimation of the number of women living with metastatic breast cancer in the United States

Angela B. Mariotto, Ruth Etzioni, Marc Hurlbert, Lynne Penberthy, Musa Mayer

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC. Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness-death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease. Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I-III breast cancer who later progressed to MBC. Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18% to 36%, for women diagnosed with de novo MBC at age 15-49 between 1992-1994 and 2005-2012, respectively. Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. population. Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population.

Original languageEnglish (US)
Pages (from-to)809-815
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Breast Neoplasms
Recurrence
Survival
Population
Registries
Epidemiology
Survival Rate
Neoplasm Metastasis
Mortality
Research

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Estimation of the number of women living with metastatic breast cancer in the United States. / Mariotto, Angela B.; Etzioni, Ruth; Hurlbert, Marc; Penberthy, Lynne; Mayer, Musa.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 6, 01.06.2017, p. 809-815.

Research output: Contribution to journalArticle

Mariotto, Angela B. ; Etzioni, Ruth ; Hurlbert, Marc ; Penberthy, Lynne ; Mayer, Musa. / Estimation of the number of women living with metastatic breast cancer in the United States. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 6. pp. 809-815.
@article{02443d70924d42e29e36c2119a96c1d5,
title = "Estimation of the number of women living with metastatic breast cancer in the United States",
abstract = "Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC. Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness-death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease. Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I-III breast cancer who later progressed to MBC. Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18{\%} to 36{\%}, for women diagnosed with de novo MBC at age 15-49 between 1992-1994 and 2005-2012, respectively. Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. population. Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population.",
author = "Mariotto, {Angela B.} and Ruth Etzioni and Marc Hurlbert and Lynne Penberthy and Musa Mayer",
year = "2017",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0889",
language = "English (US)",
volume = "26",
pages = "809--815",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Estimation of the number of women living with metastatic breast cancer in the United States

AU - Mariotto, Angela B.

AU - Etzioni, Ruth

AU - Hurlbert, Marc

AU - Penberthy, Lynne

AU - Mayer, Musa

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC. Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness-death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease. Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I-III breast cancer who later progressed to MBC. Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18% to 36%, for women diagnosed with de novo MBC at age 15-49 between 1992-1994 and 2005-2012, respectively. Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. population. Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population.

AB - Background: Distant metastatic breast cancer (MBC), including metastases found at diagnosis (de novo) and those occurring later (recurrence), represents the most severe form of the disease, when resource utilization is most intensive. Yet, the number of women living with MBC in the United States is unknown. The objective of this article is to use population-based data to estimate the prevalence of MBC. Methods: We used a back-calculation method to estimate MBC prevalence from U.S. breast cancer mortality and survival from the Surveillance, Epidemiology and End Results (SEER) registries. On the basis of the illness-death process, this method assumes that each observed breast cancer death is the result of MBC, either de novo or a recurrence with metastatic disease. Results: We estimate that by January 1, 2017, there will be 154,794 women living with MBC in the United States, three in four initially diagnosed with stage I-III breast cancer who later progressed to MBC. Median survival and 5-year relative survival for de novo MBC increased over the years, especially in younger women. We estimate a two-fold increase in 5-year relative survival rate from 18% to 36%, for women diagnosed with de novo MBC at age 15-49 between 1992-1994 and 2005-2012, respectively. Conclusions: This study demonstrates an increasing number of women in the United States living with MBC, likely the result of improvements in treatment and aging of the U.S. population. Impact: The increasing burden of MBC highlights the importance of documenting recurrence to foster more research into the specific needs of this understudied population.

UR - http://www.scopus.com/inward/record.url?scp=85020191575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020191575&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0889

DO - 10.1158/1055-9965.EPI-16-0889

M3 - Article

VL - 26

SP - 809

EP - 815

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -